If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.


Biological Chemistry

Molecular Machinery That Kicks Asthma Into Gear Is Unveiled

The blood-clotting factor fibrinogen plays an important part in triggering immune responses in the lungs, study finds

by Lauren K. Wolf
August 19, 2013 | A version of this story appeared in Volume 91, Issue 33

Asthma affects about one in 12 people in the U.S. To find treatments for the chronic disease, scientists have long sought its underlying molecular causes. David B. Corry and Farrah Kheradmand of Baylor College of Medicine, in Houston, and colleagues recently unveiled part of asthma’s molecular pathway when they reported the results of some 20 years’ worth of research in Science (2013, DOI: 10.1126/science.1240342). By studying the response of lung cells from mice and humans to fungi—a frequent asthma trigger—the team determined that fibrinogen, a glycoprotein involved in blood clot formation, helps trigger asthma symptoms. The researchers showed that fungal protease enzymes cleave fibrinogen into bits, one of which binds and activates Toll-like receptor 4 (TLR4), a protein on cells lining the lungs. This cleavage probably happens in everyone’s lungs, Corry says, but to a greater degree in the lungs of asthmatics. Then, TLR4 somehow signals the “big guns” of the immune system—helper T cells, which ultimately induce an allergic response. Designing drugs to block TLR4, though, would be “playing with fire,” Corry says, because it regulates other parts of the immune system. But finding and blocking the relevant fibrinogen fragment might be a future strategy for asthma treatment.


This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.